SCARAB GENOMICS LLC
C-Flow™ continuous culture system for efficient protein production of antibody therapeutics
- Sector
- Biotech
- Headquarters
- Madison, WI
- Total capital
- $23.8M
- Federal grants
- $23.8M
- 23 awards · 2015–2025
- Rank in peer group#2 of 13
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 11
- 20 pending · first 2016
- Rank in peer group#2 of 13
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Development of a continuous microbial fermentation system using reduced genome E. coli that undergo programmed autolysis and generate nuclease post-production for the manufacture of biopharmaceuticals$938K
- Federal grantHealth and Human S · Phase II · An improved low-endotoxin Clean Genome E. coli strain for production of biological products$806K
- Federal grantHealth and Human S · Phase II · An improved low-endotoxin Clean Genome E. coli strain for production of biological products$842K
- Federal grantHealth and Human S · Phase II · Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture$962K
- Federal grantHealth and Human S · Phase II · Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture$945K
- Federal grantHealth and Human S · Phase II · Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain$1M
- Federal grantHealth and Human S · Phase II · Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture$2.9M
Show 16 earlier federal awards
- Federal grantHealth and Human S · Phase II · Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture$1M
- Federal grantHealth and Human S · Phase II · Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli$738K
- Federal grantHealth and Human S · Phase II · Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain$1M
- Federal grantHealth and Human S · Phase II · Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli$911K
- Federal grantHealth and Human S · Phase II · Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain$3M
- Federal grantHealth and Human S · Phase II · Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain$1M
- Federal grantHealth and Human S · Phase I · Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli$156K
- Federal grantHealth and Human S · Phase II · Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli$156K
- Federal grantHealth and Human S · Phase II · Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics’ reduced genome E. coli strains$707K
- Federal grantHealth and Human S · Phase II · Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics’ reduced genome E. coli strains$878K
- Federal grantHealth and Human S · Phase II · Characterization of a low mutation rate E. coli in extended fermentation$864K
- Federal grantHealth and Human S · Phase I · Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics' reduced genome E coli strains$154K
- Federal grantHealth and Human S · Phase II · Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics’ reduced genome E. coli strains$154K
- Federal grantHealth and Human S · Phase II · Characterization of a low mutation rate E coli in extended fermentation$2.4M
- Federal grantHealth and Human S · Phase II · Characterization of a low mutation rate E. coli in extended fermentation$1.6M
- Federal grantHealth and Human S · Phase II · Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain$729K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 13 peers
Line = medianBiotech · System
- Federal grants#2 · top 15%
- Granted patents#2 · top 15%
- Linked publications#2 · top 15%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 11 granted of 31- GrantedSynthetic GenomeUSPTOUS 12,385,035
- GrantedSynthetic GenomeUSPTOUS 12,378,547
- GrantedReduced Genome E. Coli Lacking Toxin-antitoxin GenesUSPTOUS 11,970,725
Show all 31 patent records
- Synthetic GenomeAug 12, 2025 · US 12,385,035Granted
- Synthetic GenomeAug 5, 2025 · US 12,378,547Granted
- Reduced Genome E. Coli Lacking Toxin-antitoxin GenesApr 30, 2024 · US 11,970,725Granted
- Synthetic GenomeDec 7, 2023 · Application 18321475Pending
- Methods and Compositions for Improved Expression of Recombinant ProteinsJun 6, 2023 · US 11,667,944Granted
- Improved Purification Of Crm 197 From BacteriaNov 16, 2021 · US 11,174,284Granted
- Materials and Methods for Extended Continuous Flow Fermentation of Reduced Genome BacteriaOct 12, 2021 · US 11,142,745Granted
- Materials And Methods For Extended Continuous Flow Fermentation Of Reduced Genome BacteriaMar 31, 2020 · US 10,604,736Granted
- Enhanced Production of Recombinant CRM197 in E. coliNov 19, 2019 · US 10,479,820Granted
- Bacteria With Improved Metabolic CapacityJul 26, 2018 · Application 15904297Pending
- Reduced Genome Bacteria With Improved Genetic StabilityMar 13, 2018 · US 9,914,905Granted
- Bacteria With Improved Metabolic CapacityFeb 27, 2018 · US 9,902,965Granted
- Reduced Genome Bacteria With Improved Genetic StabilitySep 1, 2016 · Application 15154827Pending
- Reduced Genome Bacteria With Improved Genetic StabilityMay 17, 2016 · US 9,340,791Granted
- Reduced Genome E. ColiDec 3, 2015 · Application 14803923Pending
- Enhanced Production Of Recombinant CRM197 In E. ColiApplication PCTUS2015018338Pending
- Reduced Genome Bacteria With Improved Genetic StabilityApplication PCTUS2012061027Pending
- Compositions Comprising Reduced Genome Bacteria For Use In Treatment Of SepsisApplication PCTUS2010023774Pending
- Clean Genome BactofectionApplication PCTUS2009056829Pending
- Compositions And Methods For Amino Acid BiosynthesisApplication PCTUS2009034534Pending
- Lac Expression SystemApplication PCTUS2008084964Pending
- Plasmid Dna Preparations And Methods For Producing SameApplication PCTUS2007069685Pending
- Methods And Compositions For Producing Recombinant Proteins Using A Gene For TrnaApplication PCTUS2007067232Pending
- Oxygen-regulated MicroorganismsApplication PCTUS2006035200Pending
- Purification Of Crm 197 From BacteriaApplication PCTUS2018025969Pending
- Reduced Genome E. ColiApplication PCTUS2006032525Pending
- Purification of SCRB-981 from high density Esherichia coli fermentateApplication 62644234Pending
- Methods And Compositions For Improved Expression Of Recombinant ProteinsApplication PCTUS2018049422Pending
- Purification Of Crm 197 From BacteriaApplication 62481534Pending
- Purification Of Target MoleculesApplication PCTUS2019022687Pending
- Materials And Methods For Extended Continuous Flow Fermentation Of Reduced Genome BacteriaApplication PCTUS2016025588Pending
Recent research by its founders
- Biological Frontiers20190 cites
- Enhancing the Translational Capacity of <i>E. coli</i> by Resolving the Codon Bias201879 cites
- Enhancing the translational capacity of <i>E. coli</i> by resolving the codon bias20181 cites
Related companies, and why
- STONESTABLE, INC.Similar federal contract value in Biotech · null in contracts
- CICLOMED, LLCSimilar federal contract value in Biotech · null in contracts
- Pheon TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Ambros TherapeuticsSimilar federal contract value in Biotech · null in contracts
- EXESALIBERO, INC.Similar federal contract value in Biotech · null in contracts
- SpliceBioSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .